SCHEMBL4289362

SCHEMBL4289362

N#Cc1cc(-c2cnn(Cc3ccccc3)c2)ccc1F

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.57
PIK3CD O00329 1/20 0.49
PIK3CA P42336 1/20 0.49
PIK3CB P42338 1/20 0.49
PI4KA P42356 1/20 0.49
PIK3CG P48736 1/20 0.49
PI4KB Q9UBF8 1/20 0.49
CREBBP Q92793 5/20 0.49
KCNH2 Q12809 7/20 0.47
FLT3 P36888 1/20 0.46
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
USP30 Q70CQ3 1/20 0.44
FFAR4 Q5NUL3 1/20 0.43
GRIN2B Q13224 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3639423 0.93 L3MBTL1 (0.50) L3MBTL1PIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL3796834 0.79 CYP19A1 (0.58) FLT3
SCHEMBL27374657 0.78 L3MBTL1 (0.57) L3MBTL1PIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL19065565 0.76 L3MBTL1 (0.58) L3MBTL1PIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL19134434 0.76 FLT3 (0.45) FLT3CYP11B1CYP11B2
SCHEMBL12419620 0.75 L3MBTL1 (0.57) L3MBTL1PIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL3289673 0.74 L3MBTL1 (0.56) L3MBTL1CREBBPCYP11B1CYP11B2FFAR4
SCHEMBL2662178 0.74 LRRK2 (0.51) PIK3CDPIK3CAPIK3CBPI4KAPIK3CG
SCHEMBL15536192 0.74 L3MBTL1 (0.49) L3MBTL1PIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL1514536 0.73 FLT3 (0.59) FLT3CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
CN-101790526-A 5-heteroaryl substituted indazoles as kinase inhibitors ABBOTT GMBH & CO KG 2010-07-28 CN disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 L3MBTL1 2812/4885PIK3CD 152/4885PIK3CA 140/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 L3MBTL1 2812/4885PIK3CD 152/4885PIK3CA 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.